← Back to patent-cliff list
Salvianolic acid A (Shanghai Pharmaceuticals Holding)
Tier C — Watch / tradeSalvianolic acid A (Shanghai Pharmaceuticals Holding)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Updating
Indications (approved)：Coronary artery disease, Angina pectoris
Regional status
US
-
EU
-
China
Phase II
2022-12-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Salvianolic acid A (Shanghai Pharmaceuticals Holding)?
Approved indications include: Coronary artery disease, Angina pectoris.
When does the Salvianolic acid A (Shanghai Pharmaceuticals Holding) patent expire?
No public expiry year is available for Salvianolic acid A (Shanghai Pharmaceuticals Holding) yet; this page updates once verified.
How do I get a quote for Salvianolic acid A (Shanghai Pharmaceuticals Holding) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21